Elotuzumab in Combination with Pomalidomide and Corticosteroids for Relapsed or Refractory Multiple Myeloma

被引：0
|
作者：
Sidiqi, Hasib [1 ]
McGregor, Scott [2 ]
Baker, Ross [2 ]
Carnley, Ben [2 ]
Radeski, Dejan [1 ]
Barraclough, Allison [1 ]
Augustson, Bradley [1 ]
机构：
[1] Sir Charles Gairdner Hosp, Perth, WA, Australia
[2] Perth Blood Inst, Perth, Australia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷 / 01期
关键词：
D O I：
10.1016/j.clml.2017.03.151
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS-149
引用
收藏
页码：E83 / E84
页数：2
相关论文
共 50 条
  • [21] Pembrolizumab in Combination with Pomalidomide and Dexamethasone (PEMBRO/POM/DEX) for Pomalidomide Exposed Relapsed or Refractory Multiple Myeloma
    Wilson, Lilly
    Cohen, Adam D.
    Weiss, Brendan M.
    Vogl, Dan T.
    Garfall, Alfred L.
    Capozzi, Donna L.
    Mangan, Patricia
    Sanchez, Mary
    Erb, Colleen
    Stadtmauer, Edward
    BLOOD, 2016, 128 (22)
  • [22] Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Lonial, Sagar
    Vij, Ravi
    Harousseau, Jean-Luc
    Facon, Thierry
    Moreau, Philippe
    Mazumder, Amitabha
    Kaufman, Jonathan L.
    Leleu, Xavier
    Tsao, L. Claire
    Westland, Christopher
    Singhal, Anil K.
    Jagannath, Sundar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) : 1953 - 1959
  • [23] Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma
    Ide, Takafumi
    Osawa, Mayu
    Sanghavi, Kinjal
    Vezina, Heather E.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (01) : 129 - 140
  • [24] Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
    Dharshan Sivaraj
    Michael M Green
    Yubin Kang
    Gwynn D Long
    David A Rizzieri
    Zhiguo Li
    Anderson H Garrett
    Jackie L McIntyre
    Nelson J Chao
    Cristina Gasparetto
    Blood Cancer Journal, 8
  • [25] A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma.
    San Miguel, Jesus
    Raab, Marc S.
    Goldschmidt, Hartmut
    Lonial, Sagar
    Richardson, Paul G.
    Shelat, Suresh
    Bleickardt, Eric W.
    Palumbo, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
    Sivaraj, Dharshan
    Green, Michael M.
    Kang, Yubin
    Long, Gwynn D.
    Rizzieri, David A.
    Li, Zhiguo
    Garrett, Anderson H.
    McIntyre, Jackie L.
    Chao, Nelson J.
    Gasparetto, Cristina
    BLOOD CANCER JOURNAL, 2018, 8
  • [27] Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial
    Kumar, Sudhir
    Sharma, Atul
    Malik, Prabhat Singh
    Gogia, Ajay
    Pathak, Neha
    Sahoo, Ranjit Kumar
    Gupta, Ritu
    Prasad, Chandra Prakash
    Kumar, Lalit
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (02) : 288 - 297
  • [28] A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Gasparetto, Cristina
    Bowles, Kristian M.
    Abdallah, Al-Ola
    Morris, Lura
    Mander, Gudrun
    Coppola, Sheryl
    Wang, Jing
    Ross, Jeremy A.
    Bueno, Orlando F.
    Arriola, Emma
    Mateos, Maria Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : 775 - 784
  • [29] Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma
    Hoylman, Emily
    Brown, Anna
    Perissinotti, Anthony J.
    Marini, Bernard L.
    Pianko, Matthew
    Ye, Jing Christine
    Campagnaro, Erica
    Nachar, Victoria R.
    LEUKEMIA & LYMPHOMA, 2020, 61 (03) : 691 - 698
  • [30] FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
    Gormley, Nicole J.
    Ko, Chia-Wen
    Deisseroth, Albert
    Nie, Lei
    Kaminskas, Edvardas
    Kormanik, Natasha
    Goldberg, Kirsten B.
    Farrell, Ann T.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2017, 23 (22) : 6759 - 6763
12345